

FACULTY OF PHARMACEUTICAL MEDICINE

REVALIDATION POLICIES

POLICY: Clinical Review

VERSION: 1.0

APPROVAL DATE: February 2019

REVIEW DATE February 2024

1. Purpose

This policy sets out the basis for when an appraisee revalidating via the Faculty of Pharmaceutical Medicine must provide a Clinical Review.

2. Clinical Review

Where an appraisee has clinical work appraisers and the Responsible Officer (RO) find it very valuable for them to include, as part of their annual evidence, an informal review from their consultant or equivalent manager in the clinical setting. This is standard practice in the NHS where a doctor has clinical and academic responsibilities and such an approach is generally referred to as using the principles or guidance from part of the Follett Review. Terminology differs but it may be referred to as a performance review, clinical review, an internal, company or a corporate appraisal, a practice review, etc

To ensure that the full scope of work of a doctor's practice is available for review in the appraisal meeting, all doctors with any clinical work including patient or (healthy) volunteer contact must include such a review. This mandatory requirement for an additional piece of supporting information, complete with reflection and learnings, will provide extra evidence and reassurance to the appraiser and Responsible Officer that all aspects of a doctor's work is captured and available for discussion. This review is in addition to providing the supporting evidence mandated by the GMC for clinical work.

This requirement applies to those who are working in Phase 1 and Phase 2 units as well as all doctors with direct patient contact such as clinical attachments in the NHS, private medicine, etc. If a doctor, through the course of their clinical work, receives a review or appraisal connected to such work then it should be uploaded to PReP appropriately titled.